Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats

R Bals-Kubik, A Ableitner, A Herz and TS Shippenberg

Department of Neuropharmacology, Max-Planck Institute for Psychiatry, Martinsried, Germany.

An unbiased conditioned place preference paradigm was used to examine the neuroanatomical substrates mediating the reinforcing and aversive effects of mu and kappa opioid agonists. Unilateral microinjection of the selective mu agonist DAMGO into the ventral tegmental area (VTA), the origin of the mesolimbic and mesocortical dopamine (DA) systems, resulted in dose-dependent preferences for the drug-associated place. Intracranial injections of DAMGO into terminal projection sites of VTA DA neurons, the nucleus accumbens and the medial prefrontal cortex, however, as well as into the lateral hypothalamus, were without effect. In contrast, microinjections of the kappa agonist U50,488H and the dynorphin derivative E-2078 into the VTA produced place aversions. Place aversions were also observed after microinjections of U50,488H and E-2078 into the nucleus accumbens, medial prefrontal cortex and lateral hypothalamus. However, microinjections of mu and kappa agonists into either the origin of the mesostriatal DA system, the substantia nigra or into its major terminal field, the nucleus caudatus-putamen, was without effect. Autoradiographic studies revealed that the substances remained within a restricted area around the injection site, confirming that the effects observed were mediated therein. Thus, these data suggest an important role for the A10 neurons in the VTA in the regulation of both mu and kappa opioid-induced motivational states. The rewarding effects are associated with the activation of mu receptors in the VTA, whereas aversive effects are associated with the activation of kappa receptors in the VTA and its limbic-cortical terminal regions.

Volume 264, Issue 1, pp. 489-495, 01/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. A. Lane, A. A. Lessard, J. Chan, E. E. O. Colago, Y. Zhou, S. D. Schlussman, M. J. Kreek, and V. M. Pickel Region-Specific Changes in the Subcellular Distribution of AMPA Receptor GluR1 Subunit in the Rat Ventral Tegmental Area after Acute or Chronic Morphine Administration J. Neurosci., September 24, 2008; 28(39): 9670 - 9681. [Abstract] [Full Text] [PDF]

				M. Cs. Horvath, G. G. Kovacs, V. Kovari, K. Majtenyi, Y. L. Hurd, and E. Keller Heroin Abuse Is Characterized by Discrete Mesolimbic Dopamine and Opioid Abnormalities and Exaggerated Nuclear Receptor-Related 1 Transcriptional Decline with Age J. Neurosci., December 5, 2007; 27(49): 13371 - 13375. [Abstract] [Full Text] [PDF]

				A. T. Knoll, E. G. Meloni, J. B. Thomas, F. I. Carroll, and W. A. Carlezon Jr. Anxiolytic-Like Effects of {kappa}-Opioid Receptor Antagonists in Models of Unlearned and Learned Fear in Rats J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 838 - 845. [Abstract] [Full Text] [PDF]

				C. P. Ford, M. J. Beckstead, and J. T. Williams Kappa Opioid Inhibition of Somatodendritic Dopamine Inhibitory Postsynaptic Currents J Neurophysiol, January 1, 2007; 97(1): 883 - 891. [Abstract] [Full Text] [PDF]

				M. J. Will, W. M. Vanderheyden, and A. E. Kelley Striatal opioid peptide gene expression differentially tracks short-term satiety but does not vary with negative energy balance in a manner opposite to hypothalamic NPY Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R217 - R226. [Abstract] [Full Text] [PDF]

				C. P. Ford, G. P. Mark, and J. T. Williams Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci., March 8, 2006; 26(10): 2788 - 2797. [Abstract] [Full Text] [PDF]

				E. B. Margolis, H. Lock, V. I. Chefer, T. S. Shippenberg, G. O. Hjelmstad, and H. L. Fields {kappa} opioids selectively control dopaminergic neurons projecting to the prefrontal cortex PNAS, February 21, 2006; 103(8): 2938 - 2942. [Abstract] [Full Text] [PDF]

				M. Narita, Y. Nagumo, S. Hashimoto, M. Narita, J. Khotib, M. Miyatake, T. Sakurai, M. Yanagisawa, T. Nakamachi, S. Shioda, et al. Direct Involvement of Orexinergic Systems in the Activation of the Mesolimbic Dopamine Pathway and Related Behaviors Induced by Morphine J. Neurosci., January 11, 2006; 26(2): 398 - 405. [Abstract] [Full Text] [PDF]

				E. B. Margolis, G. O. Hjelmstad, A. Bonci, and H. L. Fields Both Kappa and Mu Opioid Agonists Inhibit Glutamatergic Input to Ventral Tegmental Area Neurons J Neurophysiol, June 1, 2005; 93(6): 3086 - 3093. [Abstract] [Full Text] [PDF]

				M. D. Recker and G. A. Higgins The Opioid Receptor Like-1 Receptor Agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) Produces a Discriminative Stimulus in Rats Distinct from That of a {micro}, {kappa}, and {delta} Opioid Receptor Agonist Cue J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 652 - 658. [Abstract] [Full Text] [PDF]

				M. Terashvili, H.-e. Wu, R. J. Leitermann, K.-c. Hung, A. D. Clithero, E. T. Schwasinger, and L. F. Tseng Differential Conditioned Place Preference Responses to Endomorphin-1 and Endomorphin-2 Microinjected into the Posterior Nucleus Accumbens Shell and Ventral Tegmental Area in the Rat J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 816 - 824. [Abstract] [Full Text] [PDF]

				J. A. Kim, K. A. Pollak, G. O. Hjelmstad, and H. L. Fields A single cocaine exposure enhances both opioid reward and aversion through a ventral tegmental area-dependent mechanism PNAS, April 13, 2004; 101(15): 5664 - 5669. [Abstract] [Full Text] [PDF]

				E. B. Margolis, G. O. Hjelmstad, A. Bonci, and H. L. Fields {kappa}-Opioid Agonists Directly Inhibit Midbrain Dopaminergic Neurons J. Neurosci., November 5, 2003; 23(31): 9981 - 9986. [Abstract] [Full Text] [PDF]

				G. O. Hjelmstad and H. L. Fields Kappa Opioid Receptor Activation in the Nucleus Accumbens Inhibits Glutamate and GABA Release Through Different Mechanisms J Neurophysiol, May 1, 2003; 89(5): 2389 - 2395. [Abstract] [Full Text] [PDF]

				M. Narita, K. Mizuo, H. Mizoguchi, M. Sakata, M. Narita, L. F. Tseng, and T. Suzuki Molecular Evidence for the Functional Role of Dopamine D3 Receptor in the Morphine-Induced Rewarding Effect and Hyperlocomotion J. Neurosci., February 1, 2003; 23(3): 1006 - 1012. [Abstract] [Full Text] [PDF]

				Z.-X. Xi and E. A. Stein GABAergic MECHANISMS OF OPIATE REINFORCEMENT Alcohol Alcohol., September 1, 2002; 37(5): 485 - 494. [Abstract] [Full Text] [PDF]

				A. Zangen, S. Ikemoto, J. E. Zadina, and R. A. Wise Rewarding and Psychomotor Stimulant Effects of Endomorphin-1: Anteroposterior Differences within the Ventral Tegmental Area and Lack of Effect in Nucleus Accumbens J. Neurosci., August 15, 2002; 22(16): 7225 - 7233. [Abstract] [Full Text] [PDF]

				M. M. Nieto, J. Wilson, A. Cupo, B. P. Roques, and F. Noble Chronic Morphine Treatment Modulates the Extracellular Levels of Endogenous Enkephalins in Rat Brain Structures Involved in Opiate Dependence: A Microdialysis Study J. Neurosci., February 1, 2002; 22(3): 1034 - 1041. [Abstract] [Full Text] [PDF]

				A. Zimmer, E. Valjent, M. Konig, A. M. Zimmer, P. Robledo, H. Hahn, O. Valverde, and R. Maldonado Absence of Delta -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice J. Neurosci., December 1, 2001; 21(23): 9499 - 9505. [Abstract] [Full Text] [PDF]

				G. O. Hjelmstad and H. L. Fields Kappa Opioid Receptor Inhibition of Glutamatergic Transmission in the Nucleus Accumbens Shell J Neurophysiol, March 1, 2001; 85(3): 1153 - 1158. [Abstract] [Full Text] [PDF]

				J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine Pharmacol. Rev., June 1, 1999; 51(2): 341 - 396. [Abstract] [Full Text] [PDF]

				A. L. Svingos, E. E. O. Colago, and V. M. Pickel Cellular Sites for Dynorphin Activation of kappa -Opioid Receptors in the Rat Nucleus Accumbens Shell J. Neurosci., March 1, 1999; 19(5): 1804 - 1813. [Abstract] [Full Text] [PDF]

				W. A. Carlezon Jr., J. Thome, V. G. Olson, S. B. Lane-Ladd, E. S. Brodkin, N. Hiroi, R. S. Duman, R. L. Neve, and E. J. Nestler Regulation of Cocaine Reward by CREB Science, December 18, 1998; 282(5397): 2272 - 2275. [Abstract] [Full Text]

				N. Altier and J. Stewart Dopamine Receptor Antagonists in the Nucleus Accumbens Attenuate Analgesia Induced by Ventral Tegmental Area Substance P or Morphine and by Nucleus Accumbens Amphetamine J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 208 - 215. [Abstract] [Full Text]

				M. F. Olive, H. N. Koenig, M. A. Nannini, and C. W. Hodge Stimulation of Endorphin Neurotransmission in the Nucleus Accumbens by Ethanol, Cocaine, and Amphetamine J. Neurosci., December 1, 2001; 21(23): RC184 - RC184. [Abstract] [Full Text] [PDF]